Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 43-49

  Meguro, Akiko ^a   Ozaki, Katsutoshi ^a   Sato, Kazuya ^a   Oh, Iekuni ^a   Fujiwara, Shinichiro ^a   Hosonuma, Rie ^a   Sasazaki, Miyuki ^a   Kikuchi, Yuji ^a   Hirata, Yuji ^a   Yamamoto, Chihiro ^a   Uesawa, Mitsuyo ^a   Kobayashi, Hiroyuki ^a   Matsu, Haruko ^a   Okabe, Hiroshi ^a   Uehara, Eisuke ^a   Nishikawa, Akinori ^a   Tatara, Raine ^a   Hatano, Kaoru ^a   Yamamoto, Chizuru ^a   Matsuyama, Tomohiro ^a   Toshima, Masaki ^a   Ueda, Masuzu ^a   Ohmine, Ken ^a   Suzuki, Takahiro ^a   Mori, Masaki ^a   Nagai, Tadashi ^a   Muroi, Kazuo ^a   Ozawa, Keiya ^a   more..

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

DLBCL; Dose reduction; Elderly; R 70 CHOP

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; COMORBIDITY; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ELDERLY CARE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFECTION; JAPANESE; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; OVERALL SURVIVAL; PARALYTIC ILEUS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 84855464786     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.600486     Document Type: Article

References (18)

1. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362: 1417-1429.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling. Nature 2000;403:503-511. (Pubitemid 30082188)
3. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifi es a clinically favorable subgroup of diff use large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862. (Pubitemid 37152922)
4. S avage KJ, Monti S, Kutok JL, et al. Th e molecular signature of mediastinal large B-cell lymphoma diff ers from that of other diff use large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-3879. (Pubitemid 37486965)
5. L enz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
6. Th e International Non-Hodgkin' s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin' s lymphoma. N Engl J Med 1993;329:987-994.
7. D ixon DO, Neilan B, Jones SE, et al. Eff ect of age on therapeutic outcome in advanced diff use histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305. (Pubitemid 16133082)
8. V ose JM, Armitage JO, Weisenburger DD, et al. Th e importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin ' s lymphoma. J Clin Oncol 1988;6:1838-1844. (Pubitemid 19089066)
9. S ehn LH, Berry B, Chhanabhai M, et al. Th e revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diff use large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
10. L yman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin ' s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311. (Pubitemid 41185151)
11. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346:235-242. Feugier P (Pubitemid 34438862)
12. Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diff use large B-cell lymphoma: a study by the Groupe d ' Etude des Lymphomes de l ' Adulte. J Clin Oncol 2005;23:4117-4126. (Pubitemid 46211317)
13. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20- B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
14. Jaff e ES, Harris NL, Vardiman J, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
15. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
16. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
17. D elarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diff use large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009;114(Suppl. 1): Abstract 406.
18. Guti é rrez A, Mestre F, P é rez-Manga G, et al. Diff use large B-cell lymphoma in the older. Crit Rev Oncol Hematol 2011;78:59-72.